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We have determined the methylation status of the CpG island of the oestrogen receptor a gene in seven human ovarian cell
lines. Cell lines expressing oestrogen receptor a showed no evidence of hypermethylation. In three of four cell lines that
produced no detectable oestrogen receptor a protein, hypermethylation was observed at the NotI site of the CpG island.
These results indicate that aberrant hypermethylation may be responsible for a signiﬁcant proportion of epithelial ovarian
tumours in which oestrogen receptor a expression is lost.
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The expression of oestrogen receptor a (ER-a) detected in the
epithelial cells of normal human ovaries is frequently lost in ovar-
ian cancers (Lau et al, 1999). ER-a expression is signiﬁcant in
epithelial ovarian cancer as, in conjunction with progesterone
receptor, it is reported as a good prognostic factor (Leake and
Owens, 1990). Silencing of a number of different genes in
tumours often arises through hypermethylation of promoter
regions. In ovarian cancer methylation has been reported for a
number of loci including BRCA1 (Baldwin et al, 2000; Strathdee
et al, 2001). The CpG island 5' of the ER-a gene has been found
to be hypermethylated in a high proportion of ER-negative breast
tumours (Lapidus et al, 1996) and in breast cell lines (Ottaviano
et al, 1994). This has also been reported in colorectal tumours
(Issa et al, 1994) and several other cancers (Issa et al, 1996; Li
et al, 2000).
We have examined ER-a expression and methylation of the ER-
a CpG island in a series of human epithelial ovarian cell lines using
the technique of methylation speciﬁc polymerase chain reaction
(MS–PCR) (Herman et al, 1996). This allows rapid and unambig-
uous determination of the methylation status of the regions of
DNA complementary to the PCR primers used.
MATERIALS AND METHODS
Cell lines
PEO 1, PEO 4, PEA 1 and PEO 14 were gifts of Dr S Langdon,
ICRF Edinburgh, UK. OAW42 was obtained from Dr A Wilson,
Derby City Hospital, UK. OTN14 was supplied by Dr M Cairns,
Department of Oncology, Queen’s University Belfast, UK. All cell
lines were maintained in RPMI 1640 (Life Science Technologies)
supplemented with 2.4 mgm l
71 insulin and 10% foetal calf serum
(PAA), in an atmosphere of 5% CO2.
Western blotting
A sub-conﬂuent culture from a 75 cm
2 ﬂask was used for protein
extraction. Cells were scraped into 1.0 ml PBS, pelleted and frozen
at 7708C. The pellet was thawed into 200 ml high salt buffer
(0.4 M KCl, 20 mM HEPES, 20% (v v
71) glycerol, 1 mM dithio-
threitol, 40 mgm l
71 PMSF and 20 mlm l
71 protease inhibitor
cocktail (Sigma). It was then syringed through a 26G needle 10–
15 times and microfuged at 13000 r.p.m. for 20 min. The superna-
tant was stored at 7708C. Protein was quantiﬁed by the BCA
method (Pierce). Proteins were electrophoresed in vertical 12%
polyacrylamide gels, at a constant current of 30 mA for 2–4 h,
and were subsequently transferred to Protran nitrocellulose using
a Mulitphor II semi-dry blot apparatus (Pharmacia), at 1 mA per
cm
2 for up to 2 h. Filters were blocked using 5% Marvel milk
powder, and ER-a detected using 1:200 dilutions of murine anti-
body to human oestrogen receptor (Dako). After washing, 1:500
dilutions of goat-anti mouse secondary antibodies were added for
1 h at room temperature. The bound antibodies were then visua-
lized by enhanced chemiluminescence using the Amersham ECL
kit as described by the manufacturer’s instructions. Restripping
of blots was achieved by immersion in a solution containing
100 mM b-mercaptoethanol, 2% (w v
71) SDS, 62.5 mM, Tris-HCl
pH 6.7, for 30 min at 608C with agitation. Tubulin detection on
blots was carried out as for ER-a except that antibody against
tubulin (Dako) was used.
MS–PCR
After treatment with Na bisulphite to induce deamination of
methylated cytosines MS–PCR was carried out by a modiﬁcation
of the method described by Lapidus et al (1996). The primers used
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www.bjcancer.comwere designed to detect methylation at the NotI site of the ER-a
promoter. The sequence of the primers for unmethylated DNA
were 5' TGTTGTTTATGAGTTTAATGTTGTGGTT 3' and 5'
AAAAAAACCCCCCAAACCATT 3'. These gave a product of
124 bp. For methylated DNA the primers were 5' ACGAGTT-
TAACGTCGCGGTC 3' and 5' ACCCCCCAAACCGTTAAAAC 3'
which gave a product of 110 bp (J Herman, private communica-
tion).
The MS–PCR conditions used for both methylated and
unmethylated primers were identical. After an initial denaturation
at 958C for 5 min Taq DNA polymerase was added and the reac-
tion continued for 35 cycles each consisting of denaturation at
958C for 30 s, annealing at 578C for 30 s and extension at 708C
for 30 s. A ﬁnal extension at 728C for 5 min was followed by
storage at 48C overnight. Products were visualized after electro-
phoresis in a 2% agarose gel for 1.5 h at 80 V.
RESULTS
We analyzed the ER-a status of six epithelial ovarian cell lines by
Western blotting. The well-characterized breast cancer cell line
MCF-7 was used as a positive control. The data presented in Figure
1A clearly indicate that of the ovarian cell lines only PEO1 and
PEO4 display a positive signal for the ER-a protein. These two cell
lines were derived from the same patient at different stages of her
treatment (Langdon et al, 1988), and thus it is not surprising that
they share the same ER-a phenotype. In each case only a single
band of 67 kDa was observed and of identical mobility to the band
present in MCF-7. The levels of expression were similar in PEO 4
and MCF-7, but reduced in PEO1. The ovarian cell lines PEO14,
A2780, OTN14 and OAW 42 were clearly negative for expression
of ER-a protein. The blots were subsequently stripped and
reprobed with tubulin antibody. Figure 1B shows that there was
no evidence of protein degradation in ER-a negative cell lines
and approximately equal loading of protein in each lane.
We then assessed whether the loss of ER-a expression in the cell
lines was associated with DNA methylation in the CpG island of
the ER gene using MS–PCR with primers designed to identify
the NotI site of the ER-a promoter. The results of these ampliﬁca-
tions are shown in Figure 2. Products of MS–PCR for each cell
line were electrophoresed in adjacent pairs of lanes. The left-hand
lane represents the product of the primers designed to amplify
unmethylated DNA and the right-hand lane the product from
primers for methylated DNA. Each cell line produced product in
only one lane. The two ER-a positive ovarian cell lines and
MCF-7 all produced bands only for the left-hand lanes and are
clearly unmethylated as would be predicted. Of the four ER-a
negative ovarian cell lines OAW42, OTN14 and A2780 each gave
a product only with the primers designed to detect methylated
DNA. PEO14 however only gave product with primers for
unmethylated DNA.
In addition we examined the methylation status of the ovarian
cell line PEA1, that has been reported as expressing ER-a at very
low levels (Langdon et al, 1990). As shown in Figure 2B it is
unmethylated at this locus.
DISCUSSION
It would appear that DNA methylation of promoter sequences is
associated with non-expression in three of the four ER-a negative
epithelial ovarian cell lines. In the case of PEO14 the loss of ER-
a expression may be due to other causes such as mutation, or
suppression through reorganization of chromatin that is indepen-
dent of methylation. We have found it impossible to induce re-
expression of ER-a in this cell line by treatment with the inhibitors
of DNA methyltransferase, 5-azacytidine or 5-aza-deoxcytidine.
This supports the suggestion that DNA methylation is not respon-
sible for the ER-negative phenotype in this cell line.
Since PEA1 only expresses ER-a at very low levels, it would
appear that lack of methylation of the ER-a GpG island is neces-
sary for expression of the gene but other factors quantitatively
regulate the level of expression of the gene. Of the three cell lines
that show methylation of the ER-a promoter OAW42 derives from
serous (Wilson et al, 1984), and OTN14 (van Niekerk et al, 1988)
from mucinous tumours. Indicating that promoter methylation is
not speciﬁc to individual ovarian cancer pathologies. The pathol-
ogy of the tumour from which A2780 was derived is not known
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Figure 1 (A) Western blot of protein extracts from ovarian cell lines
probed with antibody against ER-a Lanes: 1, PEO1; 2, PEO14; 3, A2780;
4, OTN14; 5, OAW42; 6, PEO4; 7, MCF-7. (B) The same blot stripped
and reprobed with antibody against tubulin.
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Figure 2 (A) MS–PCR of Na bisulphite-treated DNA from cell lines. Lanes 1, 2: PEO 1; lanes 2, 3: PEO 14; lanes 5, 6: A2780; lanes 7, 8: ONT 14; lanes 9,
10: OAW 42; lanes 11, 12: PEO 4; lanes 13, 14: MCF-7. Unmethylated reactions: lanes 1, 3, 5, 7, 9, 11 and 13. Methylated reactions: lanes 2, 4, 6, 8, 10, 12
and 14. M, 100 bp marker. (B) MS–PCR of Na bisulphite treated DNA from cell line PEA 1. Lane 1, unmethylated reaction; lane 2, methylated reaction; M,
100 bp ladder.
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linking phenotypes except that all lack mutations in p53. It has
been suggested that tumours displaying hypermethylation of GpG
islands have reduced frequencies of mutation at p53 (Toyota et
al, 2000).
A question can be raised as to the contribution of the loss of
ER-a expression to the malignant phenotype of the ovarian tumour
cell lines. This stems from the fact that loss of ER-a expression
through hypermethylation of promoter sequences is known to
increase with age (Toyota and Issa, 1999). As ovarian tumours arise
predominantly in women over 50 years of age it is possible that
methylation of the ER-a gene preceded the development of tumor-
igenesis. It should be noted however that none of the three
negative cell lines were heterozygous for methylation of the ER-a
gene. This may be the result of loss of one copy of the gene or
because the sequence of the ER-a promoter acts as a favoured site
for aberrant DNA methylation in tumour cells. The functional
signiﬁcance of the inactivation of ER-a will only be determined
by analyzing the growth properties of cells in which the gene has
been reactivated by treatment with inhibitors of DNA methyltrans-
ferase or histone deacetylase.
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